ImmunoBrain Checkpoint Overview
ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing a pipeline of disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBCs novel approach to the treatment of neurodegeneration is based on years of innovative scientific discoveries made by Prof. Michal Schwartz of the Weizmann Institute of Science. IBCs lead programs are being developed for the treatment of Alzheimers disease, employing a novel approach of blocking the PD-1/PD-L1 immune checkpoint pathway. In June 2017, Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, obtained the rights to IBCs research into treatment for Alzheimers disease. As part of the agreement, Lundbeck will provide the funding for, as well as participate in, additional research that will allow the identification of potential therapies for clinical trials. Lundbeck also obtained minority ownership of IBC and has the exclusive option to take over the rights and activities relating to this technology at a later date.
Cumulative Funding Raised Over Time ($)
—Oct 2017
Latest News
growth-positive
/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...
ImmunoBrain, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Francis S. Collins to its board of directors. Dr. Collins, a renowned physician-scientist and former director of the National Institutes of Health, brings extensive experience in biomedical research. His appointment is expected to bolster ImmunoBrains efforts in developing novel immunotherapies for neurodegenerative diseases, particularly Alzheimers. The company is currently conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, which targets an inhibitory immune checkpoint pathway. Supported by grants from the National Institute on Aging and the Alzheimers Association, the trial is showing encouraging interim results, with topline data expected in Q1 2026.
Management ChangesProduct Stage
growth-positive
/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...
ImmunoBrain Checkpoint Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Rochelle Walensky to its board of directors. The company is conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, aimed at treating Alzheimers disease and other forms of dementia. Dr. Walensky, with a background in infectious diseases and public health, brings valuable expertise to the company. The appointment is seen as a positive step in advancing ImmunoBrains mission to develop innovative therapies for neurodegenerative diseases. The company is supported by grants from the National Institute on Aging and the Alzheimers Association, with topline data from the trial expected in Q1 2026.
Management ChangesProduct Stage
growth-positive
Lundbeck Obtains Rights to Research that Targets Immune Checkpoint...
Lundbeck has obtained the rights to IBCs research on treatment for Alzheimers disease, specifically targeting immune checkpoint pathways. The research focuses on blocking the PD-1/PD-L1 pathway, which has shown promise in cancer treatment and could potentially be extended to neurodegenerative diseases. Lundbeck will provide funding for additional research and has the option to take over the rights and activities relating to this technology in the future. The partnership with IBC is part of Lundbecks strategy to supplement its own research activities.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 1 |
| Investors | 1 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | immunobrain.com/ |
Locations
Pinhas Sapir St 3, Ness Ziona, Israel
Photos & Videos
No files yet
ImmunoBrain Checkpoint Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsCore Technology
BiologicalsTags (10)
brain-disorderbiopharmaceuticalneurosciencealzheimers-diseasebiotechnologyneurologyimmunologypharma-companiesimmunotherapypharmaceuticalsGeographic Markets
GlobalImmunoBrain Checkpoint Financials
Undisclosed
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Seed
Funding stage
1
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
—Oct 2017
Private Equity Funding
Undisclosed Round
Oct 2017
Undisclosed
SBI JI Innovation Fund
ImmunoBrain Checkpoint Lifecycle
Cumulative Funding Raised Over Time
—Oct 2017
All Events
Undisclosed Round
Oct 2017
Undisclosed
SBI JI Innovation Fund
ImmunoBrain Checkpoint News
3 articles
growth-positive
/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...
ImmunoBrain, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Francis S. Collins to its board of directors. Dr. Collins, a renowned physician-scientist and former director of the National Institutes of Health, brings extensive experience in biomedical research. His appointment is expected to bolster ImmunoBrains efforts in developing novel immunotherapies for neurodegenerative diseases, particularly Alzheimers. The company is currently conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, which targets an inhibitory immune checkpoint pathway. Supported by grants from the National Institute on Aging and the Alzheimers Association, the trial is showing encouraging interim results, with topline data expected in Q1 2026.
Management ChangesProduct Stage
growth-positive
/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...
ImmunoBrain Checkpoint Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Rochelle Walensky to its board of directors. The company is conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, aimed at treating Alzheimers disease and other forms of dementia. Dr. Walensky, with a background in infectious diseases and public health, brings valuable expertise to the company. The appointment is seen as a positive step in advancing ImmunoBrains mission to develop innovative therapies for neurodegenerative diseases. The company is supported by grants from the National Institute on Aging and the Alzheimers Association, with topline data from the trial expected in Q1 2026.
Management ChangesProduct Stage
growth-positive
Lundbeck Obtains Rights to Research that Targets Immune Checkpoint...
Lundbeck has obtained the rights to IBCs research on treatment for Alzheimers disease, specifically targeting immune checkpoint pathways. The research focuses on blocking the PD-1/PD-L1 pathway, which has shown promise in cancer treatment and could potentially be extended to neurodegenerative diseases. Lundbeck will provide funding for additional research and has the option to take over the rights and activities relating to this technology in the future. The partnership with IBC is part of Lundbecks strategy to supplement its own research activities.
Partners
ImmunoBrain Checkpoint Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 19 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
ImmunoBrain Checkpoint Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 85/100 |
| Missing | not claimed, video or image |
| BI Verification | Vered Waxman |
| Registrar ID | 515211860 |
| Crunchbase | immunobrain-checkpoint |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Asaph Wagner |
| Updater email | asaphwagner@hotmail.com |
| Last update | 2020-08-10T00:00:00.000Z |
| Created | 2019-02-25T00:00:00.000Z |